Shots:

• The US FDA has granted BTD to sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH)
• Earlier- the company reported results of P-II PULSAR study that demonstrated sotatercept has the potential to shift the current treatment paradigm and provide benefits to patients with PAH on top of currently available therapies
• Sotatercept is an investigational agent designed to be a selective ligand trap for members of the TGF-beta superfamily to rebalance BMPR-II signaling

 ­ Ref: Businesswire | Image: Businesswire